The NHS system for ensuring people get access to effective drugs is failing people with MS. Tysabri (also known as Natalizumab) is the first ever MS drug to win approval from the National Institute for Health and Clinical Excellence (NICE). This means that as a licensed drug for people with highly relapsing remitting MS, Tysabri should be available because it is both clinically and cost effective for the NHS to provide.
As a result, the MS Society is launching a campaign to improve equity of access to Tysabri across the country. We want people with MS to have the freedom to choose between all available treatments. The MS Society shall be working with Primary Care Trusts to ensure NICE decisions get implemented, as we have done already in Wakefield.
To offer your support to this campaign, please visit http://www.mssociety.org.uk/get_involved/campaigning/join_campaign.html